Interview with the Innovators

PSMA PET Imaging in Patients with Oligometastatic Prostate Cancer

Video Library —November 15, 2021
Dr Neal Shore discusses the importance of PSMA PET imaging across a range of PSA values and how PYLARIFY® (piflufolastat F 18) will affect imaging of patients with oligometastatic prostate cancer.
Related Articles
Ovarian Function Suppression in Premenopausal Breast Cancer: Are We Making Progress in Educating Patients on When to Start Therapy and the Length of Therapy?
Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG, Emily Beard, RN, BSN, OCN, CBCN
|
Video Library
Hear from two breast cancer nurse navigators, Emily Beard, RN, BSN, OCN, CBCN, and Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG, on the progress made in educating patients on when to start ovarian function suppression and the recommended duration of therapy.
How Well Do Patients Tolerate Ovarian Function Suppression? Oncology Nurse Navigators Discuss Their Experience
Emily Beard, RN, BSN, OCN, CBCN, Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG
|
Video Library
This Interview with the Innovator video features breast cancer nurse navigators Emily Beard, RN, BSN, OCN, CBCN, and Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG, as they discuss ovarian function suppression, how patients tolerate side effects, and educating patients on expectations of treatment.
Ovarian Suppression: What Are Some of the Important Questions That Women Ask?
Emily Beard, RN, BSN, OCN, CBCN, Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG
|
Video Library
Emily Beard, RN, BSN, OCN, CBCN, and Melissa Simon, BSN, RN, OCN, CBCN, ONN-CG, examine fertility issues associated with ovarian function suppression and the psychosocial impact it has on young breast cancer patients.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country